

# pMONO-blasti-mcs

Single expression cassette plasmid for the expression of one gene of interest

Catalog code: pmonob-mcs

<https://www.invivogen.com/pmono-blasti>

For research use only

Version 20F16-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of pMONO-blasti-mcs plasmid provided as lyophilized DNA
- 2 x 1 ml blasticidin at 10 mg/ml

### Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

## GENERAL PRODUCT USE

pMONO plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfecants and offer a choice of selectable markers. pMONO plasmids contain a unique transcription unit that drives the expression of the gene of interest and the selectable marker through an internal ribosome entry site (IRES). This dual gene expression system ensures that stable clones express the gene of interest. Transcription of the expression cassette is efficiently terminated by the late SV40 polyadenylation signal (polyA).

## PLASMID FEATURES

- **SV40/FerH/mEF1 $\alpha$ :** pMONO plasmids feature a composite ferritin promoter that confers strong and constitutive expression in a wide range of mammalian cells. The promoter is composed of the ferritin heavy chain (FerH) core promoter<sup>1</sup> fused at its 5' end to the SV40 enhancer, and at its 3' end to the intron-containing 5'UTR of the mouse elongation factor 1 alpha gene. This composite promoter yields similar levels of expression as the CMV promoter in all cell lines tested.

- **MCS:** The multiple cloning site contains the following restriction sites:

5' - Age I, EcoR V, BamH I, Mlu I, Cla I, Sal I, Avr II - 3'

Each restriction site is unique and compatible with many other enzymes, increasing the cloning options.

- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression<sup>2</sup>.

- **Blasti:** Resistance to Blasticidin is conferred by the *bsr* gene from *Bacillus cereus*. The *bsr* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>3</sup>.
- **Ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

## METHODS

### Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

### References

1. Eisenstein RS. & Munro HN. 1990. Translational regulation of ferritin synthesis by iron. Enzyme 44(1-4):42-58.
2. Ramesh N et al. 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res. 24(14):2697-700.
3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell Biol. 10: 4248-4258.

## RELATED PRODUCTS

Product	Description	Cat. Code
ChemiComp GT116 cells	Competent <i>E. coli</i> cells	gt116-11
Blasticidin	Selection antibiotic	ant-bl-05

## TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



**SdaI (6)**

1 **CCTCAGGGCTGAAATAACCTCTGAAAGAGGAACCTGGTAGTACCTCTGAGGCTGAAAGAACAGCTGTGGAATGTGTCAGTTAGGTGTGAA**

101 **AGTCCCCAGGCTCCCAGCAGGCAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGAAAGTCCCAGGCTCCAGCAGGCAAG**

201 **TATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTC**C**ACTAGTCCCGCAGAGCGCGCAGGGGCTCCAGGGCCCTCCACAGCAGG**

301 **GCGGGTCCCGCCACCGAAGGAGCGGCTGGGGCGGCCTGATTGGCGGGCGCTGACGCCAGCAGGCTATAAGAGACCAAGCG**

401 **ACCCGAGGCCAGCAGTCTCGCGAAGCTGCGCTCAGAACGCAAGT**C**AGGTGAGGGGGCTGGCTCGCCGAGCTGGAGGTCTGCTCGCCGAGCTGGAGGTCTGCTCC**

501 **AGCGGGCCGGCCCCGCTGTCGCGGGATTAGCTGCGAGCATTCCGCTTCAGTTGCGGGCGCGAGGAGCTGAGGTGAGGCTAGCGGCAA**

601 **CCCCGTAGCCTCGCCCTCGTGTCCGCTTGAGGCTAGCGTGTGTCGCGCCGCGCGCTACTCCGCGCACTCTGGTTTTTTTTGTT**

701 **GTTGTTGCCCTGCTGCCCTGATTGCCGTTCAAGCAATAGGGCTAACAAAGGGAGGTGCGGGGCTTGCTCGCCCGAGCCGGAGAGGTATGGTGGG**

801 **GAGGAATGGAGGGACAGGAGTGGCGCTGGGGCCCTCGGAGCACATGTCGACGCCACCTGGATGGGCGAGGCTGGGTTTCCGAAG**

901 **CAACCAAGGCTGGGGTAGCGTGCCAGGCCATGTGGCCCCAGCACCGCACGATCTGGCTTGCGGCCGCTGGCCCTGCCCTAACTAGGGTGA**

1001 **GGCCATCCCCTCCGGACCAGTTGCGTGTGAAAGATGGCCCTCCGGCCCTGGCAAGGAGCTAAATGGAGGACGCCAGCCGGTGAGC**

1101 **GGGCGGGTGAGTCACCCACAAAGGAAGGGGCTGGCCCTACCGGCTGCTGCTTGTGACCCGTTGAGACTATGCCGCAATAGTCACCTCG**

1201 **GCTTTGAGCACGGCTAGTCGGGGGGGGGGGATGTAATGGCGTGGAGTTGTCACATTGGGGGAGACTAGTCAGGCCAGCCTGGCG**

1301 **GGAAGTCATTTGAAATTGCTCCCTGAGTTGAGCGGAGCTAATTCTGGCTTCTAGCGGTTCAAAGGTATTTAACCTTTAGGTGT**

**SmaI (1049)**

1001 **GGCCATCCCCTCCGGACCAGTTGCGTGTGAAAGATGGCCCTCCGGCCCTGGCAAGGAGCTAAATGGAGGACGCCAGCCGGTGAGC**

1101 **GGGCGGGTGAGTCACCCACAAAGGAAGGGGCTGGCCCTACCGGCTGCTGCTTGTGACCCGTTGAGACTATGCCGCAATAGTCACCTCG**

1201 **GCTTTGAGCACGGCTAGTCGGGGGGGGGGGATGTAATGGCGTGGAGTTGTCACATTGGGGGAGACTAGTCAGGCCAGCCTGGCG**

**EcoNI (1391)**

1301 **GGAAGTCATTTGAAATTGCTCCCTGAGTTGAGCGGAGCTAATTCTGGCTTCTAGCGGTTCAAAGGTATTTAACCTTTAGGTGT**

**EcoRV (1436) MluI (1446) SalI (1459)**

1401 **TGTGAAAACCACCGTAATTCAAAGCA**CCGGT**ATATCGGATCCACCGTATCG**A**TTGTCACCC**T**AG**G**ACGGTTCCAA**T**AC**G**AC**A**GGTTCCCAATGACACAAACGTGC**

1501 **AACTTGAAACTCCGCTGGCTTCCAGGTCTAGAGGGTAACACTTGACTGCGTTGGCTCACGCTCGATCCACTGGGAGTGTAGTAACAGCAC**

1601 **TGTTGCTCGAGCGGAGCATGACGGCGTGGAACTCTCTTGTAAACAAGGACCCACGGGGCAAAGGCCACCCCCAACGGGGCGTATGTGTC**

1701 **AACCCAGCAGCGACTTACTGCAAACCCACTTAAAGTGAATTGACATTGAAACTGGTACCCACACACTGGTACAGGCTAAGGATGCCCTCAGGTACCC**

**Eco47III (1856) HindIII (1869)**

1801 **CGAGGTAACACCGGACACTCGGGATCTGAGAAGGGACTGGGCTCTATAAAAGCGCTCGTTAAAAGCTCTATGCCGAATAGGTGACCGGAGGT**

**AseI (1956)**

1901 **CGGCACCTTCCTTGCAATTACTGACCCATGA**A**ACTGACTGTTGACAA**T**ATCGGCATAGTATATGCCATAGTATAATCGACTCACT**

**XmnI (2016)**

2001 **ATAGGAGGGCACC**A**TAGAACCTCTCACATCTCAGCAGGATCTGGAGCTGGAGGTCGCCACTGAGAACATCACCAGCTCTATGAGGACAAACAA**A****

2101 **GCACCATGTCGGGGCGG**C**ATCAGGACAA**G**ACTGGGAGATCATCTGTCGTCACATTGAGGGCTACTTGGCAGGGTCACTGCTGCTGAGGCC**

2201 **29▶SHiShiSValGlyAlAlAlLeArgThrLysThrGlyGlyIleIleSerAlAlAlValHisIleGluAlAlAlTyrIleGlyArgValThrValCysAlAlGluAla**

2301 **63▶IleAlAlIleGlySerAlAlValSerAsnGlyIlnLysAspPheAspThrIleValAlAlValArgHiSProTyrSerAspGluValAspArgSerIleArgV**

2301 **96▶AlValSerProCysGlyMetCysArgGluLeuIleSerAspTyrAlAlProAspCysPheValLeuIleGluMetAsnGlyLysLeuValLysThrThrI**

**NheI (2448)**

2401 **TGAGGAACATCCCCCTCAAGTACACCGAACTAA**ACCTGAA**TTGCTAG**G**CCAGACATGATAAGATACATTGATGAGTTGGACAAACACAA**C**AC**

129▶eGluIleLeuIleProLeuLysTyrThrArgAsn●●●

2501 **TAGAATGCA**G**AGTAAAAATGCTTATTGAAATTGATGCTATTGCTTATTGTAACCATTAAAGCTGCAATAAACAAAGTTAACAAACAAAT**

**HpaI (2588) MfeI (2597)**

2601 **TGCATTCTATTGTTCAAGGTCAGGGGAGGTGAGGTTTTAAAGCAAGTAAACCTCTACAAATGTGGTATG**GAA**ATGTTAAACTAGC**

2701 **CATGACCAAAATCCCTAACGTGAGTTCTGTTCACTGAGCGTCAGACCCGTAAGAAAGATCAAAGATCTTCTGAGATCCTTTCTGCGCTA**

2801 **ATCTGCTGCTGCAAACAAAAACCCGCTACAGCGGTGGTTGTTGCCGATCAAGAGCTACCAACTCTTCTGAGGTAACGGCTCAG**

2901 **GAGCGCAGATACAAACTGTTCTAGTGTAGCCGTAGTTAGGCCACACTCAAGAACTCTGAGCACGCCACATACCTGCTGCTAATCCT**

3001 **GTTACCACTGCTGCGCACTGGGATAAGTCGTTACCGGGTTGACTCAAGACGATAGTTACCGGATAAGCGCAGCGGTGGCTGAACGGG**

**ApaLI (3106)**

3101 **GGTCGTCACACAGCCAGCTGGAGCGAACCTACCGAAC**T**AC**G**AGATAC**C**AGCGT**G**AG**C**T**A**TGAGAAAGCGCCACGCTCCGAAGGGAGAA**

3201 **AGGCGGACAGGTATCGGTAAGCGGACGGGCTGGAACAGGAGAGCGCAGAGGGAGCTCCAGGGGAAACGCCTGGTATCTTATAGTCTGCGG**

3301 **TCGCCACCTCTGACTTGAGCGTCATTGATGCTCGTCAAGGGGGCGAGCCTATGAAAAAACGCCAGCAACCGCCCTTTACGGTCTGGCC**

**PacI (3432)**

3401 **TTTGCTGGCTTTGTCACATGTTCTAATTAA**